Osteonecrosis is a disorder characterized by death of the cellular elements of the bone. It has been associated with many disorders, but knowledge of its pathophysiology remains incomplete. One association is with the use of corticosteroids, including their use in patients with inflammatory bowel disease (IBD). The mechanism of steroid-induced osteonecrosis remains obscure. Some people have questioned whether osteonecrosis that occurs in patients given corticosteroids for chronic inflammatory diseases is actually due to the underlying systemic disease rather than the corticosteroids, although it has been widely described. Two cases of osteonecrosis have been reported in patients with Crohn’s disease before they began taking corticosteroids (2). Relatively few patients with IBD who take corticosteroids suffer from osteonecrosis. Whether or not corticosteroids contribute to the risk of osteonecrosis, there may be other described factors that predispose some patients with IBD to this bone complication.

Osteonecrosis in a patient with Crohn’s disease unrelated to corticosteroid use

Ali Khan MD1, Gerald Illiffe MD2, Donald S Houston MD PhD2, Charles N Bernstein MD2,3

A Khan, G Illiffe, DS Houston, CN Bernstein. Osteonecrosis in a patient with Crohn’s disease unrelated to corticosteroid use. Can J Gastroenterol 2001;15(11):765-768. Osteonecrosis is a feared complication of corticosteroid use. However, a direct association between corticosteroid use and osteonecrosis has never been proven. The present report examines the case of a patient with longstanding Crohn’s disease who had never been treated with corticosteroids and who developed osteonecrosis of the talus. The association of systemic inflammatory disorders with osteonecrosis and the possible association with vascular thrombosis are discussed.

Key Words: Corticosteroids; Crohn’s disease; Osteonecrosis

Osteonécrose chez un patient souffrant de la maladie de Crohn, non liée aux corticostéroïdes

RÉSUMÉ : L’ostéonécrose est une complication redoutée des corticostéroïdes. Toutefois, le lien direct entre les deux n’a jamais été établi. Voici le cas d’un patient souffrant depuis longtemps de la maladie de Crohn, qui n’a jamais été traité aux corticostéroïdes et chez qui est apparue une ostéonécrose de l’astragale. Il sera donc question, dans le présent article, du lien entre les troubles inflammatoires généraux et l’ostéonécrose et du lien possible avec la thrombose vasculaire.
but who suffered from osteonecrosis (3). We report a patient with Crohn's disease of 30 years' duration who had never been treated with corticosteroids and who presented with osteonecrosis of the talus. This case provides further evidence that osteonecrosis in a patient with Crohn's disease may be more likely to be disease-related than corticosteroid-related.

**CASE PRESENTATION**

In 1966, a 14-year-old female patient presented with abdominal pain, diarrhea, weight loss and anorexia, and a perianal fistula. Sigmoidoscopy revealed distal colorectal inflammation. She was treated with antibiotics. Nine months later, she underwent a laparotomy, which revealed a thickened, indurated and adherent terminal ileum, ascending colon and proximal one-third of the transverse colon. An ileal resection plus right hemicolectomy with end-to-end ileocolonic anastomosis was performed. The pathology was consistent with Crohn's disease. In 1968, the patient underwent a second laparotomy for recurrent obstructive symptoms. At surgery, the patient was found to have a thickened and edematous colon with a normal small bowel. The ileocolonic anastomosis was resected, and a permanent ileostomy was created.

Over the next nine years, the patient was hospitalized five times per year, on average, for intermittent bowel obstructions. She was treated medically with sulfasalazine 1.5 g/day, and at no time did she receive corticosteroids. In 1977, she underwent a third laparotomy, which revealed a thickened mesentery, and a stenotic and thickened distal ileum. Twelve centimetres of neoterminal ileum was resected, and the end ileostomy was recreated.

Over the ensuing 19 years, she had multiple hospitalizations for recurrent small bowel obstructions. Her medical management as an inpatient never included corticosteroids, and as an outpatient, she was maintained on 5-aminosalicylic acid (Asacol, Procter & Gamble Pharmaceuticals, Canada) and cod liver oil for the latter 15 years. During disease exacerbations, she frequently complained of diffuse arthralgias, but she never suffered from frank arthritis.

In 1996, she was admitted with an incomplete small bowel obstruction. At that time, she complained of increased arthralgias at her ankles, hips, hands and left knee. She had sustained no trauma to any of her joints. She gave no history of alcohol ingestion and had never been treated with total parenteral nutrition (TPN). On physical examination, she had abdominal findings consistent with a small bowel obstruction and bilateral ankle swelling. Her ankle x-rays revealed collapse, with subchondral sclerosis of the talar dome consistent with osteonecrosis, and there also were secondary osteoarthritic degenerative changes (Figure 1). There was osteopenia at her left hip and knee, and her wrists and sacroiliac joints.

---

**Figure 1** Plain films of ankles. The bones are generally undermineralized. There is extensive soft tissue swelling around the ankle. The findings are indicative of advanced avascular necrosis of the talar domes. **Left**: Fracture is evident at the tip of the medial malleolus; there is fissuring, sclerosis and irregularity at the dome of the talus. **Right**: There is evident flattening or collapse of the talar dome.
time of disease quiescence for a variety of coagulation parameters. Protein C, protein S and antithrombin III levels were within normal limits. The factor V Leiden or prothrombin mutations were not present. The serum homocysteine level was elevated at 16.7 µmol/L (normal less than 13 µmol/L), and the factor VIII level was markedly elevated at 538%. Her tissue plasminogen activator antigen level was elevated at 12.1 ng/mL (normal 1.4 to 8.4 ng/mL), and the plasminogen activator inhibitor (PAI) activity was at the upper end of normal at 10.6 U/mL (normal less than 0.1 to 11.0 U/mL). Her lipoprotein (a) level was 449 U/L (normal 0 to 300 U/L). At the time that these levels were measured, the C-reactive protein level was less than 4 mg/L.

DISCUSSION

Our patient developed osteonecrosis after nearly 30 years of recurrently active Crohn’s disease without ever being treated with corticosteroids. Osteonecrosis was reported in the early part of the 20th century, long before corticosteroids were introduced therapeutically (6). There has been a paucity of reports of osteonecrosis in IBD. It was first reported in a patient with Crohn’s disease taking corticosteroids and was then reported in three teenagers who were receiving corticosteroids plus TPN for active Crohn’s disease (7-8). Because the authors of the pediatric series had not seen osteonecrosis previously among their patients with Crohn’s disease treated with corticosteroids or among their TPN-treated patients, they postulated that the mechanism was based on the combination of corticosteroid use and TPN (perhaps through elevated lipid profiles systemically and locally within bones) (8). Later, seven patients (4.3%) in a series of 161 corticosteroid-treated Crohn’s disease patients were reported to have osteonecrosis (9). The authors concluded that corticosteroids were to blame for the osteonecrosis in their IBD patients. However, there was no control group of IBD patients who had not received corticosteroids. In this study, the mean cumulative dose of prednisone was only 7 g, whereas in two other series of patients with organ transplants or SLE who developed osteonecrosis, the mean cumulative prednisone doses were 42 and 45 g, respectively (10,11). This may further support the hypothesis that IBD itself poses a risk for the development of osteonecrosis. In a number of reports of patients with SLE, no relationship was evident between corticosteroids and osteonecrosis (12-14). Kenzora and Glimcher (1) suggested that corticosteroids alone likely do not cause osteonecrosis. Administration of corticosteroids to healthy laboratory animals has failed to induce osteonecrosis (1,4,5). In humans, there have been few reported cases of osteonecrosis developing in patients receiving corticosteroids for nonsystemic medical problems. None of 6000 head trauma patients treated with high dose corticosteroids over a 10-year period at the University of Maryland (College Park, USA) developed osteonecrosis (1).

A hypothesis that has been put forward regarding the pathogenesis of osteonecrosis is impaired vascular flow to bone, with subsequent cell death. One mechanism postulated for the impaired flow is vascular thrombosis; patients with IBD have increased rates of venous thromboembolism (15), and some investigators have postulated a vasculitis theory of Crohn’s disease pathogenesis (16). In one series of patients with idiopathic osteonecrosis (not associated with any underlying inflammatory condition or use of corticosteroids), 15 of 18 patients had a definable disorder predisposing them to thrombosis (17). In this report, there were three subjects with osteonecrosis who had no underlying associated risk factor of any type, including systemic disease, corticosteroid use, or a definable thrombophilic or hypofibrinolytic disorder. There is one case report in the literature of a child with severe protein C deficiency who presented with hip osteonecrosis at a time when therapeutic coumadin administration led to a suboptimal international normalized ratio (18). The formation of small fibrin thrombi in the circulation of patients with Crohn’s disease may lead to osteonecrosis by progressively occluding epiphyseal capillaries (19). Perhaps the strongest evidence for a correlation between hypercoagulability and osteonecrosis is a study that reported 59 patients with hip osteonecrosis, of whom 41% were homezoygous for the 4G/4G polymorphism of the PAI-1 gene compared with 20% of a control group (P=0.001) (20). The gene product of the 4G polymorphism, hypofibrinolytic PAI activity, was higher in osteonecrosis patients than in controls (median 19.2 U/mL versus 6.3 U/mL, P=0.0001).

Our patient had a very elevated level of circulating factor VIII, a mildly elevated level of homocysteine and a high lipoprotein (a) level. These were measured during a period of inactive inflammatory disease (corroborated by the level of C-reactive protein) and thus are likely constitutional. Both elevated factor VIII and elevated homocysteine levels can predispose a person to vascular thrombosis (21-24), although neither has been associated with osteonecrosis thus far. Disturbances of fibrinolysis, particularly, elevation of lipoprotein (a), have been the most common abnormalities identified in osteonecrosis (17). Impaired fibrinolysis has also been reported to be a feature of Crohn’s disease (18). Another hypothesized mechanism for osteonecrosis that arises in patients with multisystem diseases is the impairment of osteoblast function by circulating cytokines (25). The lack of osteoblasts to repair small microfractures may increase the susceptibility of a person to osteonecrosis by another factor such as corticosteroids. However, we propose that the predisposition to thrombosis may be an important factor associated with osteonecrosis, particularly during periods of increased disease activity.

CONCLUSIONS

We report the case of a patient with longstanding Crohn’s disease who never used corticosteroids and who presented with osteonecrosis of the talus. This patient had some abnormalities in coagulation parameters. We contend that
hypercoagulability may be related to osteonecrosis. Therefore, consideration should be given to checking the coagulation profiles of patients with unexplained osteonecrosis. Osteonecrosis in Crohn’s disease remains sufficiently uncommon; it is thus premature to consider screening all patients with Crohn’s disease for coagulation parameters. Corticosteroids may contribute to the risk profile of osteonecrosis, but this remains only conjecture. As our case proves, osteonecrosis can occur in patients with Crohn’s disease who do not use corticosteroids.

**ACKNOWLEDGEMENTS:** Charles N Bernstein MD is supported by a Manitoba Medical Services Foundation Clinical Research Professorship. Donald S Houston MD PhD is supported by the Heart and Stroke Foundation of Canada.

**REFERENCES**

